A Study to Evaluate the Safety and Efficacy of 2ccPA in Patients With Symptomatic Knee Osteoarthritis

Osteoarthritis, Knee Clinical Trial

Official title:

A Phase I-II, Dose-escalation, Double-blinded, Placebo-controlled, and Dose-finding Study to Evaluate the Safety and Efficacy of 2ccPA in Patients With Osteoarthritis of the Knee

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT05807529
• Other study ID #: OEP-2PM102-201
• Status: Active, not recruiting
• Phase: Phase 1/Phase 2
• Start date: November 3, 2022
• Est. completion date: December 2024

Study information

• Verified date: March 2024
• Source: Orient Europharma Co., Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This phase I/II study aims to evaluate the safety of single doses of 2ccPA 4,800 μg and 7,200 μg (Phase I), as well as the safety and efficacy of multiple doses of 2ccPA (Phase II) in patients with osteoarthritis (OA) of the knee.

Description:

Osteoarthritis (OA) is a degenerative disease frequently associated with symptoms such as inflammation, stiffness, muscle weakness, joint swollen and joint pain. 2-carba-cyclic phosphatidic acid (2ccPA) is the derivative of natural occurring phospholipid mediator, cyclic phosphatidic acid (cPA). Previous studies suggested that 2ccPA inhibits inflammation and may relieve the pain caused by osteoarthritis. This phase I/II study aims to evaluate the safety of single doses of 2ccPA 4,800 μg and7,200 μg (Phase I), as well as the safety and efficacy of multiple doses of 2ccPA (Phase II) in patients with osteoarthritis (OA) of the knee.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 136
• Est. completion date: December 2024
• Est. primary completion date: December 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 40 Years to 80 Years

Eligibility

Inclusion Criteria:

1. Signed written informed consent from any patient capable of giving consent.

2. Male or female patients, 40 to 80 years of age.

3. Documented clinical diagnosis of symptomatic OA affecting at least one knee of a minimum of 6 months prior to screening.

4. The study knee has OA of Grade 2 to 3 severity based on the Kellgren Lawrence grading scale.

5. A score > 6 and < 16 out of 20 on the WOMAC pain subscale for the study knee.

6. Pain in the study knee for most of the 30 days (i.e., more than half of the days) prior to randomization.

7. Women of childbearing potential must agree to practice a medically acceptable contraceptive regimen from screening visit until at least 1 month after the study treatment and must have a negative pregnancy test no earlier than 72 hours prior to study treatment. Male subjects must agree to practice a medically acceptable contraceptive regimen (i.e., sterilization surgery, barrier method, abstention) from screening visit until at least 1 month after the study treatment.

Exclusion Criteria:

1. Patients with known or suspected hypersensitivity to 2ccPA or any of its excipients.

2. Use of intra-articular corticosteroids, hyaluronic acid, or other IA injection in the study knee within 3 months prior to study entry (randomization).

3. Use of chondroitin and/or glucosamine within 4 weeks prior to study entry (randomization).

4. Administered or requiring systemic or topical treatment of the study knee joint including immunosuppressive agents, anti-inflammatory drugs, steroids, or opioids for knee OA within 1 week prior to randomization. Acetaminophen (oral daily dose = 3000 mg or topical use at any dose) can be taken up to 24 hours prior to randomization. For long-acting steroids (i.e., dexamethasone, betamethasone), subjects who received systemic treatment within 2 weeks before randomization will be excluded.

5. History of post-traumatic knee arthritis, or evidence of intra-articular bleeding of the study knee.

6. History of reiter's syndrome, gouty arthritis, systemic lupus erythematosus (SLE), sicca syndrome, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, lymphoma, arthritis associated with inflammatory bowel disease, sarcoidosis, amyloidosis or any other immune disease that based on investigators' discretion.

7. Periarticular inflammation from any cause, including referred pain, bursitis, tendonitis, soft tissue tenderness or acute pain from injury.

8. Subjects with clinical signs and symptoms of active knee infection or being treated for knee infection at screening.

9. Arthroscopic or open surgery on the study knee within 6 months prior to study entry (randomization).

10. Prior knee replacement on the study knee or planned knee replacement during the study period.

11. Subjects with meniscus tears that require repairment surgery or known anterior cruciate ligament rupture.

12. Subjects with known severe synovitis, synovium necrosis in the study knee joint.

13. Subjects with known malignancy.

14. Use of any chemotherapeutic or systemic immunosuppressant agents for inflammatory diseases within 6 months prior to study entry (randomization).

15. Current use of anticoagulants, including warfarin, heparin, low molecular weight heparin, dabigatran, or factor Xa inhibitors (rivaroxaban, apixaban, edoxaban, and betrixaban). Subject requiring routine use of low-dose aspirin for preventing thrombosis (= 100 mg/day) will not be excluded.

16. Abnormalities of laboratory parameters as described below will qualify for exclusion:

• hemoglobin < 8 g/dL
• total white blood cell count < lower limit of normal (LLN)
• serum bilirubin/ alanine aminotransferase (ALT)/ aspartate aminotransferase AST > 2.5 times upper limit of normal (ULN)
• serum creatinine > 2 times ULN

17. Pregnancy or lactation.

18. History of drug or alcohol dependence in the past 3 years.

19. Having known infection with HIV-1, active hepatitis B, or active hepatitis C. Patients who are inactive carriers of HBV or HCV can be enrolled if the subjects have stable baseline condition during the screening period.

20. Use of any investigational drug or participation in any drug study within 4 weeks prior to study entry (randomization).

21. Subjects unwilling or unable to comply with study procedures.

22. Any clinical condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk to participate in the study or confounds the ability to interpret data from the study as judged by the investigator.

Related Conditions & MeSH terms

• Osteoarthritis
• Osteoarthritis, Knee

Intervention

Drug:
• 2ccPA
2-carba-cyclic phosphatidic acid (2ccPA) is a first-in-class phospholipase autotaxin (ATX) inhibitor that may act as a disease-modifying drug and may relieve OA associated symptoms. Phase I: 2 dose cohorts (4800µg, 7200µg) single dose at Day 1 Phase II: 3 dose cohorts (2400µg, 4800µg, 7200µg) multiple dose at Day 1, 15, 29
• Placebo
Phase I: 2 dose cohorts (4800µg, 7200µg) single dose at Day 1 Phase II: 3 dose cohorts (2400µg, 4800µg, 7200µg) multiple dose at Day 1, 15, 29

Locations

Country	Name	City	State
Taiwan	Tri-Service General Hospital	Taipei

Sponsors (1)

Lead Sponsor	Collaborator
Orient Europharma Co., Ltd.

Country where clinical trial is conducted

Taiwan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To define maximum tolerated dose (MTD) following the intra-articular (IA) administration of a single ascending dose (SAD) 2ccPA in patients with osteoarthritis of the knee.		85 Days
Primary	To evaluate the safety of 2ccPA including incidence of adverse events (AEs) and serious adverse events (SAEs).		85 Days
Primary	To evaluate the efficacy of multiple doses of 2ccPA vs placebo in terms of changes in the Western Ontario and McMaster Universities Arthritis Index (WOMAC) on Day 85	The Western Ontario and McMaster Universities Osteoarthritis (WOMAC) is a widely-used, proprietary outcome measurement tool used to evaluate the condition of subjects with Osteoarthritis (OA) of the knee and hip, including pain (5 questions), stiffness (2 questions) and physical functioning (17 questions) of the joints. Each question is scored on a scale of 0-4, which corresponds to: None (0), Mild (1), Moderate (2), Severe (3), and Extreme (4).	85 Days
Secondary	To evaluate the efficacy of 2ccPA vs placebo in terms of changes in Western Ontario and McMaster Universities Osteoarthritis (WOMAC) on Day 15, 29, 57 and 168	WOMAC questionnaire consists of 24 items divided into 3 subscales: Pain (5 items), Stiffness (2 items), Physical Function (17 items). The scores for each subscale are summed up, with a possible score range of 0-20 for Pain, 0-8 for Stiffness, and 0-68 for Physical Function. Higher scores on the WOMAC indicate worse pain, stiffness, and functional limitations.	85 Days
Secondary	To evaluate the efficacy of 2ccPA vs placebo in terms of proportion of subjects with a 20% (WOMAC20), 50% (WOMAC50), and 70% (WOMAC70) improvement in the Western Ontario and McMaster Universities Osteoarthritis (WOMAC) on Days 15, 29, 57, 85 and 168		168 Days
Secondary	To evaluate the efficacy of 2ccPA vs placebo in terms of pain assessed by Numeric Rating Scale (NRS) on Days 15, 29, 57, 85 and 168.	NRS is an 11-point numeric scale ranges from '0' indicating "no pain" to '10' indicating "extreme pain".	168 Days
Secondary	To evaluate the efficacy of 2ccPA vs placebo in terms of changes in Joint Space Narrowing (JSN) measured by x-ray on Day 168		168 Days
Secondary	Maximum plasma concentration (Cmax) of 2ccPA	Pharmacokinetic profile of 2ccPA	168 Days
Secondary	Time to maximum plasma concentration (Tmax) of 2ccPA	Pharmacokinetic profile of 2ccPA	168 Days
Secondary	Area under plasma concentration-time curve (AUC0-infinity and AUC0-t) of 2ccPA	Pharmacokinetic profile of 2ccPA	168 Days
Secondary	Apparent total body clearance (CL/F) of 2ccPA	Pharmacokinetic profile of 2ccPA	168 Days
Secondary	Apparent volume of distribution (Vz/F) of 2ccPA	Pharmacokinetic profile of 2ccPA	168 Days
Secondary	Elimination half-life (t1/2) of 2ccPA	Pharmacokinetic profile of 2ccPA	168 Days